Skip to main content

Prior Authorization Criteria for Enzyme Replacement Therapy Procedure Codes J0217 and J2508 Effective February 1, 2024

Last updated on

Note: Texas Medicaid managed care organizations (MCOs) must provide all medically necessary, Medicaid-covered services to Medicaid members who are enrolled in their MCO. Administrative prcedures, such as prior authorization, precertification, referrals, and claims and encounter data filing, may differ from traditional Medicaid (fee-for-service) and from MCO to MCO. Providers should contact the member’s specific MCO for details.

Effective for dates of service on or after February 1, 2024, prior authorization will be required for enzyme replacement therapy velmanse alfa-tycv (Lamzede), procedure code J0217, and pegunigalsidase alfa-iwxj (Elfabrio), procedure code J2508.

Prior Authorization Requirements

Prior authorization is required for velmanse alfa-tycv (Lamzede), procedure code J0217, and pegunigalsidase alfa-iwxj (Elfabrio), procedure code J2508.

Velmanse alfa-tycv (Lamzede), procedure code J0217, is indicated to treat non-central nervous system manifestation of alpha-mannosidosis in adult and pediatric clients and may be reimbursed with diagnosis code E771. The pregnancy status of female clients of reproductive potential must be verified prior to the start of treatment.

Pegunigalsidase alfa-iwxj (Elfabrio), procedure code J2508, is indicated for the treatment of adult clients with confirmed Fabry disease and may be reimbursed with diagnosis code E7521.

For more information, call the TMHP Contact Center at 800-925-9126.